The identification of specific SNPs associated with type 2 diabetes comorbid depression paves the way for personalized medicine approaches, where SIRT1-targeted therapies might be developed to manage or mitigate the effects of this comorbidity. Here, SIRT1 is linked to major depressive disorder.